
    
      The study is investigating the effect and safety of stem cells therapy in patients with liver
      cirrhosis that is specifically caused by Hepatitis B infection, the participants will be
      chosen based on inclusive and exclusive criteria to ensure the eligibility of the patients
      for this study. The patients will be given therapy in the form of allogeneic mesenchymal stem
      cells transplantation, the stem cells in this study were provided from Prodia Stem Cell
      Indonesia (ProSTEM). The stem cells being will also be subjected to certain criteria to
      ensure safety. The data of this study will be derived from the observation results of the
      patients' liver damage status in weeks 4, 6 and 12. Aside from that, hemodynamic will be
      conducted as a part of the observation
    
  